Esperion Therapeutics (ESPR) EBITDA Margin (2019 - 2026)
Esperion Therapeutics (ESPR) reported EBITDA Margin of 31.45% for Q1 2026, up 3079.0% on a YoY basis from 0.99% in Q1 2025, and down 185.69% quarter-over-quarter from 36.71% in Q4 2025.
Esperion Therapeutics (ESPR) EBITDA Margin (2019 - 2026) Analysis & Trends
Esperion Therapeutics has reported EBITDA Margin for 8 years, with the latest figure at 31.45% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 3079.0% year-over-year to 31.45%; the trailing twelve-month figure through Mar 2026 stood at 1.77% (up 5725.0% YoY), and the FY2025 full-year result was 5.63%, up 994.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 31.45%, down from 36.71% in the prior quarter.
- The five-year high for EBITDA Margin was 44.3% in Q1 2024, with the low at 352.2% in Q2 2022.
- Historically, EBITDA Margin has averaged 130.45% across 5 years, with a median of 83.87% in 2024.
- The largest YoY upside for EBITDA Margin was 83741 bps in 2022 against a maximum downside of 24480 bps in 2022.
- Esperion Therapeutics' EBITDA Margin stood at 294.38% in 2022, then surged by 41 bps to 174.71% in 2023, then surged by 82 bps to 30.85% in 2024, then jumped by 219 bps to 36.71% in 2025, then tumbled by 186 bps to 31.45% in 2026.
- The last three EBITDA Margin figures came in at 31.45% (Q1 2026), 36.71% (Q4 2025), and 35.89% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -1.01% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 22.74% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -170.35% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -16.25% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 21.55% |
| 10 | Esperion Therapeutics | 49.69 Mn | -118.16 Mn | 45.53 Mn | -31.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.45% |
| Dec 31, 2025 | 36.71% |
| Sep 30, 2025 | -35.89% |
| Jun 30, 2025 | -15.45% |
| Mar 31, 2025 | -62.24% |
| Dec 31, 2024 | -30.85% |
| Sep 30, 2024 | -57.18% |
| Jun 30, 2024 | -83.87% |
| Mar 31, 2024 | 44.30% |
| Dec 31, 2023 | -174.71% |
| Sep 30, 2023 | -121.43% |
| Jun 30, 2023 | -193.65% |
| Mar 31, 2023 | -253.68% |
| Dec 31, 2022 | -294.38% |
| Sep 30, 2022 | -289.32% |
| Jun 30, 2022 | -352.20% |
| Mar 31, 2022 | -302.42% |
| Dec 31, 2021 | -423.02% |
| Sep 30, 2021 | -481.55% |
| Jun 30, 2021 | -107.40% |